Diabetes drug may help women avoid weight gain after quitting smoking
The diabetes drug dulaglutide (Trulicity) may significantly lower a woman's risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published...
View ArticleMIT engineers develop 'vibing belly' pill to control appetite and curb obesity
When you eat a large meal, your stomach sends signals to your brain that create a feeling of fullness, which helps you realize it's time to stop eating.
View ArticleGLP-1R agonist liraglutide rapidly improves insulin sensitivity in...
A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can...
View ArticleDiabetes drugs may help curb alcohol dependence
In social media posts on the community network Reddit, users reported reduced cravings for alcohol when taking drugs intended to treat Type 2 diabetes and obesity.
View ArticleDietary factors influencing GLP-1 secretion: a new perspective in diabetes...
Researchers in The American Journal of Clinical Nutrition review the impact of diet on GLP-1 secretion in metabolic conditions like obesity and type 2 diabetes, highlighting its potential in treatment...
View ArticleFermented foods linked to mental health benefits through gut-brain connection
Researchers explore the mental health benefits of fermented foods on the microbiota-gut-brain axis, highlighting the need for further studies to understand their therapeutic potential.
View ArticleBreakthrough obesity treatments on the horizon, rivaling surgery's success
New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric...
View ArticleWhat does the future hold for obesity medication development?
The safety, clinical implications, and challenges of obesity pharmacotherapies based on entero-pancreatic hormone- treatments.
View ArticleNew weight loss drug may be an effective strategy for preventing or treating...
The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for...
View ArticleAMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.
View ArticleUnderutilized obesity treatments could transform patient health
When someone has obesity, losing even 5% of their body weight can make a major difference in their health -- especially if they can keep from regaining it.
View ArticleBariatric surgery outperforms medical management in long-term diabetes control
People with type 2 diabetes who underwent bariatric surgery achieved much better long-term blood glucose control compared to people who received medical management plus lifestyle interventions,...
View ArticleExercise, GLP-1 receptor agonist, or combined approach explored in year-long...
Researchers compare the extent of weight loss after one-year termination of active intervention with GLP-1 receptor agonist, exercise, or combination.
View ArticleGut bacteria diversity linked to body weight, athletes show healthier profiles
Systematic review reveals gut microbiome variations correlate with body composition changes across lifespan, highlighting differences between obese individuals and athletes.
View ArticleNew hope for binge eating and bulimia: GLP-1 drugs could be the key
GLP-1 receptor agonists show promise in reducing binge eating behaviors in disorders like bulimia nervosa, offering a new avenue for treatment with minimal side effects.
View ArticleStudy reveals mechanisms behind antidepressant effects of diabetes drug
Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression.
View ArticleDiabetes drug dulaglutide may reduce symptoms of depression
The current study highlighted the antidepressant effects of dulaglutide using the CMS depression model. Notably, the potential metabolisms that underlie the antidepressant effect of dulaglutide have...
View ArticleNew research sheds light on how GLP-1 obesity drugs may change food cravings
GLP-1 analog treatments potentially alter food preferences and reduce obesity by decreasing appetite and food consumption, with further research needed for long-term weight maintenance using objective...
View ArticleAI-based analysis uncovers two plant extracts with potential as GLP-1 agonist...
Two plant compounds with potential as GLP-1 agonist weight loss pills have been identified in an AI (artificial intelligence)-based study, the European Congress on Obesity (ECO 2024) (Venice 12-15...
View ArticleTreating early-stage heart failure in diabetic patients: Insights from...
One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes did not meet its primary endpoint, but a preplanned subgroup analysis found a statistically...
View Article
